SEL 212

Drug Profile

SEL 212

Alternative Names: Non-immunogenic uricase; Pegadricase-SVP; Pegsiticase-SVP; SEL-037/SEL-110; SEL-212; SVP-Rapamycin/pegsiticase

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Selecta Biosciences
  • Class Antigouts; Enzymes; Oxidoreductases; Polyethylene glycols; Recombinant proteins; Synthetic vaccines
  • Mechanism of Action Urate oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout

Most Recent Events

  • 07 Dec 2016 Efficacy and Adverse events data from a phase Ia and phase Ib trials in Hyperuricaemia released by Selecta Biosciences
  • 01 Dec 2016 Selecta Biosciences completes a phase I trial in Gout in USA (NCT02648269)
  • 26 Oct 2016 Phase-II clinical trials in Gout in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top